Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
6.8
3.9
Journals
Biomedicines
Special Issues
Asthma and Allergy: New Therapeutic Frontiers and Patient Perspectives in...
share announcement

Asthma and Allergy: New Therapeutic Frontiers and Patient Perspectives in a Changing World

A special issue of Biomedicines (ISSN 2227-9059). This special issue belongs to the section "Molecular and Translational Medicine".

Deadline for manuscript submissions: 31 May 2026 | Viewed by 441

Special Issue Editors

Prof. Dr. Maria Teresa Ventura

E-Mail Website
Guest Editor
Medical School, University of Bari “Aldo Moro”, Bari, Italy
Interests: asthma; allergy; internal medicine; digital health; health-related quality of life; biologics
Special Issues, Collections and Topics in MDPI journals
Dr. Antonio Francesco Maria Giuliano

E-Mail Website
Guest Editor
Clinica Medica “A. Murri”, Department of Preventive and Regenerative and Ionian Area (DiMePre-J), University of Bari “Aldo Moro”, AOUC Policlinico Hospital, Bari, Italy
Interests: asthma; allergy; internal medicine; digital health; health-related quality of life; biologics
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Asthma and allergic diseases remain major global health challenges, increasingly influenced by demographic, social, and environmental change. Advances in biologics, novel vaccines, and digital tools have reshaped pathogenetic hypotheses and therapeutic approaches, yet their integration into patient care requires a deeper understanding of both medical and societal contexts. Furthermore, gender medicine has become a relevant topic in the current scientific debate. Biological mechanisms and treatment strategies can differ greatly, leading to radically diverse approaches.

This Special Issue, “Asthma And Allergy: New Therapeutic Frontiers And Patient Perspectives In A Changing World”, invites original research articles, reviews, and clinical studies that explore innovative diagnostic and therapeutic approaches. We particularly welcome contributions on severe asthma and allergy, biologic therapies, vaccine development, digital health applications, precision medicine, and the exploration of sex- and gender-differences in pathogenesis and treatment. By bridging molecular mechanisms and real-world evidence, this collection aims to provide a multidisciplinary forum that reflects the complexity of managing asthma and allergy today.

We encourage clinicians and researchers to contribute and share insights that can guide the future of patient-centered management, ensuring that science and practice remain aligned with the diverse needs of individuals worldwide.

Prof. Dr. Maria Teresa Ventura
Dr. Antonio Francesco Maria Giuliano
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • asthma
  • allergy
  • biologics
  • vaccines
  • digital health
  • precision medicine
  • severe asthma
  • gender medicine

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (1 paper)

Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

23 pages, 1686 KB  
Article
Clinical Remission in Severe Asthma: A Comparative Analysis of Patients with and Without Biologics from the Swiss Severe Asthma Registry
by Fabienne Jaun, Maria Boesing, Giorgia Lüthi-Corridori, Pierre-Olivier Bridevaux, Florian Charbonnier, Christian F. Clarenbach, Jean-Marc Fellrath, Pietro Gianella, Anja Jochmann, Lukas Kern, Nikolay Pavlov, Tsogyal Daniela Latshang, Christophe Von Garnier and Joerg Daniel Leuppi
Biomedicines 2025, 13(12), 3074; https://doi.org/10.3390/biomedicines13123074 - 12 Dec 2025
Viewed by 326
Abstract
Background: Severe asthma is a complex chronic airway disease. Biologic therapies are targeted monoclonal antibody treatments used in patients with uncontrolled, severe asthma, but real-world data from long-term registries and on patients who remain biologic-naïve are limited. This study compared severe asthma [...] Read more.
Background: Severe asthma is a complex chronic airway disease. Biologic therapies are targeted monoclonal antibody treatments used in patients with uncontrolled, severe asthma, but real-world data from long-term registries and on patients who remain biologic-naïve are limited. This study compared severe asthma patients with and without biologic therapy and identified predictors of key clinical remission components. Methods: In this cross-sectional analysis of adult patients from the Swiss Severe Asthma Registry (SSAR), we compared patients treated with a biologic for ≥6 months to biologic-naïve patients (never exposed to biologics). Baseline characteristics were summarized descriptively. Multivariable logistic regression was used to identify predictors of four remission components: good asthma control (ACT ≥ 20), absence of exacerbations, no maintenance oral corticosteroid (OCS) use, and preserved lung function (FEV1 > 80% predicted). Results: Of 394 patients, 298 (75.6%) were biologic-treated and 96 (24.4%) were biologic-naïve. Biologic-treated patients more often had allergic asthma and type-2–related comorbidities, and showed better outcomes, including fewer exacerbations (0.49 vs. 1.09/year; p < 0.001) and higher ACT scores (20.0 vs. 17.2; p < 0.001). Biologic therapy was independently associated with higher odds of asthma control (OR 3.96; p = 0.006), no exacerbations (OR 5.11; p = 0.001), no OCS use (OR 6.27; p = 0.002), and FEV1 > 80% predicted (OR 4.42; p = 0.011). Overall, 24.2% of biologic-treated patients and 6.2% of biologic-naïve patients fulfilled all four remission components. Conclusions: In this real-world registry cohort, biologic-treated patients were more likely to meet individual and composite remission criteria than biologic-naïve patients. The relatively low proportion of patients achieving all four stringent criteria highlights the need to revisit current remission definitions and to adopt individualized, multidimensional treatment goals in severe asthma. Full article
(This article belongs to the Special Issue Asthma and Allergy: New Therapeutic Frontiers and Patient Perspectives in a Changing World)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-1
Back to TopTop